Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial
Work
Year: 2007
Type: article
Source: The Lancet
Institutions University of Helsinki, GlaxoSmithKline (Belgium), Institut Català d'Oncologia, Institut d'Investigació Biomédica de Bellvitge, Hospital de Clínicas de Porto Alegre +18 more
Cites: 24
Cited by: 1,295
Related to: 10
FWCI: 112.1
Citation percentile (by year/subfield): 100
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: closed